Enalaprilat increases PPARβ/δ expression, without influence on PPARα and PPARγ, and modulate cardiac function in sub-acute model of daunorubicin-induced cardiomyopathy

European Journal of Pharmacology

Volumn 714, Issue 1-3, 2013, Pages 472-477

  Cernecka, Hana ^a   Ochodnicka Mackovicova, Katarina ^a   Kucerova, Dana ^a   Kmecova, Jana ^a   Nemcekova, Viera ^b   Doka, Gabriel ^a   Kyselovic, Jan ^a   Krenek, Peter ^a   Ochodnicky, Peter ^a   Klimas, Jan ^a  

^a Physics and Informatics   (Slovakia)

^b Hospital of Ministry of Defense   (Slovakia)

Author keywords

ACEi (Angiotensin conversing enzyme inhibitor); Anthracycline; Cardiomyopathy; PPAR (Peroxisome proliferator activated receptors)

Indexed keywords

DAUNORUBICIN; ENALAPRILAT; ISOPRENALINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; HEART CONTRACTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QT PROLONGATION; RAT; UPREGULATION;

ACEI (ANGIOTENSIN CONVERSING ENZYME INHIBITOR); ANTHRACYCLINE; CARDIOMYOPATHY; PPAR (PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS);

ANIMALS; CARDIOMYOPATHIES; DAUNORUBICIN; DISEASE MODELS, ANIMAL; ENALAPRILAT; GENE EXPRESSION REGULATION; HEART; HEMODYNAMICS; PPAR DELTA; PPAR-BETA; RATS; RATS, WISTAR;

EID: 84885473117     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.06.040     Document Type: Article

References (38)

1. Adeghate, E., Hasan, M.Y., Ponery, A.S., Nurulain, S.M., Petroianu, G.A., 2005. Subchronic exposure to high-dose ACE-inhibitor moexipril induces catalase activity in rat liver. Mol. Cell. Biochem. 280, 159-163. (Pubitemid 41829813)
2. Ainger, L.E., Bushore, J., Johnson, W.W., Ito, J., 1971. Daunomycin: a cardiotoxic agent. J. Natl. Med. Assoc. 63, 261-267.
3. Braissant, O., Foufelle, F., Scotto, C., Dauca, M., Wahli, W., 1996. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137, 354-366. (Pubitemid 26005011)
4. Boucek Jr., R.J., Steele, A., Miracle, A., Atkinson, J., 2003. Effects of angiotensin-converting enzyme inhibitor on delayed-onset doxorubicin-induced cardio-toxicity. Cardiovasc. Toxicol. 3, 319-329. (Pubitemid 38055999)
5. Boucek Jr., R.J., Dodd, D.A., Atkinson, J.B., Oquist, N., Olson, R.D., 1997. Contractile failure in chronic doxorubicin-induced cardiomyopathy. J. Mol. Cell Cardiol. 29, 2631-2640. (Pubitemid 27466486)
6. Chao, H.H., Liu, J.C., Hong, H.J., Lin, J.W., Chen, C.H., Cheng, T.H., 2011. L-carnitine reduces doxorubicin-induced apoptosis through a prostacyclin-mediated pathway in neonatal rat cardiomyocytes. Int. J. Cardiol. 146, 145-152.
7. Desvergne, B., Wahli, W., 1999. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20, 649-688. (Pubitemid 30650602)
8. Ghyselinck, N.B., Bavik, C., Sapin, V., Mark, M., Bonnier, D., Hindelang, C., Dierich, A., Nilsson, C.B., Hakansson, H., Sauvant, P., Azais-Braesco, V., Frasson, M., Picaud, S., Chambon, P., 1999. Cellular retinol-binding protein I is essential for vitamin A homeostasis. EMBO J. 18, 4903-4914. (Pubitemid 29443793)
9. Gilde, A.J., van der Lee, K.A., Willemsen, P.H., Chinetti, G., van der Leij, F.R., van der Vusse, G.J., Staels, B., van Bilsen, M., 2003. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ. Res. 92, 518-524. (Pubitemid 36368664)
10. Jensen, B.V., Nielsen, S.L., Skovsgaard, T., 1996. Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy. Lancet 347, 297-299. (Pubitemid 26041043)
11. Jucker, B.M., Doe, C.P., Schnackenberg, C.G., Olzinski, A.R., Maniscalco, K., Williams, C., Hu, T.C., Lenhard, S.C., Costell, M., Bernard, R., Sarov-Blat, L., Steplewski, K., Willette, R.N., 2007. PPARdelta activation normalizes cardiac substrate metabolism and reduces right ventricular hypertrophy in congestive heart failure. J. Cardiovasc. Pharmacol. 50, 25-34. (Pubitemid 47220443)
12. Klimas, J., Vaja, V., Vercinska, M., Kyselovic, J., Krenek, P., 2012. Discrepant regulation of QT (QTc) interval duration by calcium channel blockade and angiotensin converting enzyme inhibition in experimental hypertension. Basic Clin. Pharmacol. Toxicol. 111, 279-288.
13. Kmecova, J., Klimas, J., 2010. Heart rate correction of the QT duration in rats. Eur J Pharmacol 641, 187-192.
14. Li, Y., Cheng, L., Qin, Q., Liu, J., Lo, W.K., Brako, L.A., Yang, Q., 2009. High-fat feeding in cardiomyocyte-restricted PPARdelta knockout mice leads to cardiac over-expression of lipid metabolic genes but fails to rescue cardiac phenotypes. J. Mol. Cell Cardiol. 47, 536-543.
15. Lipshultz, S.E., Lipsitz, S.R., Sallan, S.E., Simbre 2nd, V.C., Shaikh, S.L., Mone, S.M., Gelber, R.D., Colan, S.D., 2002. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J. Clin. Oncol. 20, 4517-4522. (Pubitemid 35402954)
16. Lockyer, P., Schisler, J.C., Patterson, C., Willis, M.S., 2010. Minireview: Won't get fooled again: the nonmetabolic roles of peroxisome proliferator-activated receptors (PPARs) in the heart. Mol. Endocrinol. 24, 1111-1119.
17. Liu, J., Wang, P., He, L., Li, Y., Luo, J., Cheng, L., Qin, Q., Brako, L.A., Lo, W.K., Lewis, W., Yang, Q., 2011. Cardiomyocyte-restricted deletion of PPARbeta/delta in PPARalpha-null mice causes impaired mitochondrial biogenesis and defense, but no further depression of myocardial fatty acid oxidation. PPAR Res. 2011, 372854.
18. Madrazo, J.A., Kelly, D.P., 2008. The PPAR trio: regulators of myocardial energy metabolism in health and disease. J. Mol. Cell Cardiol. 44, 968-975.
19. Mitra, M.S., Donthamsetty, S., White, B., Mehendale, H.M., 2008. High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity. Toxicol. Appl. Pharmacol. 231, 413-422.
20. Maeda, A., Honda, M., Kuramochi, T., Tanaka, K., Takabatake, T., 1997. An angiotensin-converting enzyme inhibitor protects against doxorubicin-induced impairment of calcium handling in neonatal rat cardiac myocytes. Clin. Exp. Pharmacol. Physiol. 24, 720-726. (Pubitemid 27376232)
21. Moravec, C.S., Schluchter, M.D., Paranandi, L., Czerska, B., Stewart, R.W., Rosenkranz, E., Bond, M., 1990. Inotropic effects of angiotensin II on human cardiac muscle in vitro. Circulation 82, 1973-1984.
22. Nousiainen, T., Vanninen, E., Rantala, A., Jantunen, E., Hartikainen, J., 1999. QT dispersion and late potentials during doxorubicin therapy for non-Hodgkin's lymphoma. J. Intern. Med. 245, 359-364. (Pubitemid 29202212)
23. Oudit, G.Y., Kassiri, Z., Patel, M.P., Chappell, M., Butany, J., Backx, P.H., Tsushima, R.G., Scholey, J.W., Khokha, R., Penninger, J.M., 2007. Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc. Res. 75, 29-39. (Pubitemid 46873522)
24. Pellieux, C., Montessuit, C., Papageorgiou, I., Lerch, R., 2009. Angiotensin II down-regulates the fatty acid oxidation pathway in adult rat cardiomyocytes via release of tumour necrosis factor-alpha. Cardiovasc. Res. 82, 341-350.
25. Rozen, S., Skaletsky, H., 2000. Primer3 on the WWW for general users and for biologist programmers. Methods Mol. Biol. 132, 365-386.
26. Robinson, E., Grieve, D.J., 2009. Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease. Pharmacol. Ther. 122, 246-263.
27. Sacco, G., Bigioni, M., Evangelista, S., Goso, C., Manzini, S., Maggi, C.A., 2001. Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur. J. Pharmacol. 414, 71-78. (Pubitemid 32174877)
28. Singal, P.K., Iliskovic, N., 1998. Doxorubicin-induced cardiomyopathy. N. Engl. J. Med. 339, 900-905. (Pubitemid 28446849)
29. Simunek, T., Sterba, M., Popelova, O., Adamcova, M., Hrdina, R., Gersl, V., 2009. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol. Rep. 61, 154-171.
30. Stathopoulos, G.P., Papadopoulos, N.G., Stephanopoulou, A., Dontas, I., Kotsarelis, D., Karayannacos, P.E., 1996. An increase of serum lipids after cumulative doses of doxorubicin and epirubicin in experimental animals. Anticancer Res. 16, 3429-3433. (Pubitemid 27084993)
31. Sugawara, A., Takeuchi, K., Uruno, A., Ikeda, Y., Arima, S., Kudo, M., Sato, K., Taniyama, Y., Ito, S., 2001. Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells. Endocrinology 142, 3125-3134. (Pubitemid 32575551)
32. Tham, D.M., Martin-McNulty, B., Wang, Y.X., Wilson, D.W., Vergona, R., Sullivan, M. E., Dole, W., Rutledge, J.C., 2002. Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. Physiol. Genomics 11, 21-30. (Pubitemid 37128718)
33. Todorov, V.T., Desch, M., Schmitt-Nilson, N., Todorova, A., Kurtz, A., 2007. Peroxi-some proliferator-activated receptor-gamma is involved in the control of renin gene expression. Hypertension 50, 939-944. (Pubitemid 350287538)
34. Toko, H., Oka, T., Zou, Y., Sakamoto, M., Mizukami, M., Sano, M., Yamamoto, R., Sugaya, T., Komuro, I., 2002. Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy. Hypertens. Res. 25, 597-603.
35. van Bilsen, M., Smeets, P.J., Gilde, A.J., van der Vusse, G.J., 2004. Metabolic remodelling of the failing heart: the cardiac burn-out syndrome? Cardiovasc. Res. 61, 218-226. (Pubitemid 38091762)
36. Wouters, K.A., Kremer, L.C., Miller, T.L., Herman, E.H., Lipshultz, S.E., 2005. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br. J. Haematol. 131, 561-578. (Pubitemid 43899624)
37. Yang, Q., Li, Y., 2007. Roles of PPARs on regulating myocardial energy and lipid homeostasis. J. Mol. Med. (Berlin) 85, 697-706. (Pubitemid 47063523)
38. Zhao, M., Sun, L., Liu, J.J., Wang, H., Miao, Y., Zang, W.J., 2012. Vagal nerve modulation: a promising new therapeutic approach for cardiovascular diseases. Clin. Exp. Pharmacol. Physiol. 39, 701-705.